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Genomic knowledge and technology have developed rapidly over the last decade and increased our 
capabilities to diagnose and manage rare diseases.  However, current genomic datasets lack ethnic 
diversity as many genomic studies have focused on participants of white European ancestry.  Studies, such 
as the Deciphering Developmental Disorders study, have been available to participants of any ancestry but 
have been unsuccessful in recruiting diverse populations.  The inclusion of diverse populations in exome 
and genome sequencing is important to ensure that clinical benefits of genomics advances are equally 
shared amongst all populations and to advance scientific knowledge.  Our clinical and research experience 
with the British Pakistani population (the largest ethnic minority in Yorkshire and Humber, accounting for 
4.3% of the population) has fostered the development of an innovative cultural competence framework to 
enhance the inclusion of diverse populations in clinical genomic research and service provision.  The 
application of this framework has the potential to guide healthcare professionals to develop a wide range 
of competences, so they are ready to embrace genomic advances in order to improve health outcomes for 
all patients.  This practice model will inform precision medicine and improve access of diverse populations 
to genomic studies.  Although based upon work with the Pakistani population in the UK, it is anticipated 
that the model would be broadly applicable to all underrepresented populations across the world. 
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Although independently rare, genetic disorders occur in almost 6% of the United Kingdom (UK) population 
(Genetic Alliance UK, 2018).  These disorders have significant physical, emotional, social and financial 
implications for the patients and their families.  Many rare disorders have a variety of complex phenotypes 
and pose a significant diagnostic dilemma, preventing access to therapeutic interventions, definitive 
recurrence risks, prenatal diagnosis and pre-implantation genetic diagnosis.  Next-generation sequencing 
has revolutionized genetic testing in terms of speed, cost and improved diagnostic rates.  In the UK, the 
national Deciphering Developmental Disorders (DDD) study utilized exome sequencing to identify the 
molecular basis for developmental disorders in approximately 13,500 children, achieving a diagnostic yield 
of approximately 40% with trio analysis (DDD, 2018).  The DDD study was followed by the clinical 100,000 
Genomes Project (GEL, 2017).  The UK government recently announced its intention to sequence 5,000,000 
genomes over the next five years through National Health Service (NHS) patients (GEL, 2018) and a new 
Genomic Medicine Service has been launched (NHSE, 2018).  Exome and genome sequencing is now 
becoming routine in clinical practice and increasingly blurring the line between clinical practice and 
research.  Likewise, the data from clinical testing is utilized in anonymized form in genomic databases.  The 
increased availability of genomic testing has lead to ‘mainstreaming’ (moving the responsibility for 
organizing genomic testing and dealing with the results from specialist genetics services to mainstream 
specialties). 
Within this context, the lack of ethnic diversity in current genomic datasets raises major concerns and 
restricts the clinical utility and benefits of genomic advances (Adeyemo & Rotimi, 2014; Sirugo, Williams, & 
Tishkoff, 2019).  The inclusion of diverse populations in exome and genome sequencing is critical to ensure 
that clinical benefits of genomics advances are equally shared amongst all populations and to advance 
scientific knowledge (Bentley, Callier, & Rotimi, 2017). 
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Importance of ethnic diversity in genomic research 
Interpretation of genomic variants is often difficult.  Interpretation of variants is based upon databases 
such as ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), gnomAD (https://gnomad.broadinstitute.org/) 
and DECIPHER (https://decipher.sanger.ac.uk/) and in silico analyses to try to identify the effect on the 
protein. Variants may be benign polymorphisms, alter drug metabolism, be modifying factors, cause 
disease only in the presence of another pathogenic variant or be independently disease-causing.  
Interpretation of these variants increases our understanding of the pathology of the disease, supports 
accurate diagnosis and risk determination and informs clinical pathways.  However, because genomic 
variants differ between populations, inclusion of diverse populations in genomic research greatly increases 
the interpretive power of genomic databases (Cornel & Bonham, 2017).  Despite this, a recent review of 
genome-wide association studies (GWAS) showed that 88-90% of genomic studies to date have focused on 
white European ancestry (Mills & Rahal, 2019), which only accounts for 16% of the global population.  This 
over-representation disadvantages other ethnic population groups, and contributes to existing health 
disparities (Curtis, 2018; Martin et al., 2019; Sirugo et al., 2019). 
The Yorkshire Regional Genetics Service covers a population of about 4 million, with the largest ethnic 
minority population, British Pakistanis, making up 4.3% of the local population (ONS, 2011).  Local data 
(unpublished) from the DDD study showed that the uptake by the British Pakistani population (69 
accepted/ 166 invited = 42%) was significantly lower than the white population (560 accepted/ 662 invited 
= 85%) (χ2 = 136.9; df = 1; p = 1.24-31).  Consanguineous marriages are common in British Pakistani 
population, with 37.5% of babies of Pakistani origin born in Bradford being from first-cousin marriages 
(Sheridan et al., 2013).  These unions lead to unequal distribution of founder pathogenic variants across 
populations, which contribute to a higher burden of rare, mainly autosomal recessive (AR) disorders 
(Hamamy et al., 2011).  In the DDD study, only 3.6% of European ancestry patients were found to have an 
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AR disorder compared with 31% of Pakistani ancestry patients (Martin et al., 2018).  Detection of the 
autozygous (identical by descent) pathogenic variants in consanguineous families is helpful for the 
individual family but also advances clinical and scientific knowledge by identifying new disease genes or 
proving pathogenicity of a specific genomic variant (Woods et al., 2006).  The inclusion of patients with 
consanguineous parents aids research on genetic determinants of complex diseases such as diabetes and 
coronary artery disease, as homozygotes demonstrate stronger phenotypic effects than heterozygotes 
(Saleheen et al., 2017).  Studies identifying non-disease causing autozygous genomic variants in probands 
or relatives also add to genetic knowledge by proving these genomic variants are polymorphisms 
(Narasimhan et al., 2016).  The inclusion of populations practicing consanguinity, therefore, has direct 
clinical and diagnostic advantages. 
The homogeneity of genomic data and lack of data from consanguineous populations restricts genomic 
knowledge and the ability to interpret variants for the whole population, thereby restricting diagnostic 
abilities.  In addition, this prevailing trend in genomic studies (whether clinical or research) will further 
increase the existing health disparities (Martin et al., 2019).  Therefore, an understanding of the factors 
leading to ethnic disparities in genomic studies, as well as an understanding of what drives and facilitates 
inclusion, is essential to improve access of underrepresented populations in genomics. 
Barriers to engaging diverse population in genomic research 
There are many barriers hindering engagement of ethnic minority populations in genomics, e.g. lack of 
knowledge amongst those at risk of genetic disorders, low uptake of genomic services, inadequately 
coordinated health services and lack of health policies to facilitate equity of access (Darr et al., 2015; 
Salway et al., 2019).  Lack of ethnic diversity in genomics may be partially attributed to social structures 
and practical barriers such as financial constraints and transportation difficulties.  Other barriers to the 
acceptance of genomic testing can be cultural values, family dynamics and religious beliefs, emotional and 
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psychological burdens associated with perceptions of genetic diagnosis and its implications for the wider 
family (Sanderson et al., 2013).  In addition, perceptions of the research benefits, language difficulties, lack 
of understanding, fear of genomic information, mistrust in research, confidentiality concerns and social 
determinants of health may all create barriers (Skyers, 2018). 
 
The British public’s understanding of genomics is not keeping pace with genomic advances and there are 
uncertainties about the social, legal and ethical impacts of genomics (GEL, 2019).  This may be more of an 
issue for ethnic minorities, who have specific cultural and communication needs, so more effort and 
investment is required to engage them.  A study exploring the views of people from UK Black African and 
Black Caribbean communities showed a lack of organizational commitment, economic support, policies, 
practice, strategic vision and leadership in engaging these participants in the 100,000 genomes project 
(Skyers, 2018).  Literature focusing on ethnic disparities in genomic research have shown the need for a 
global approach, strategic vision, funding, development of skilled workforce, community engagement 
programs promoting equitable access to genomics (Bentley et al., 2017; Mathew et al., 2017), but little 
progress has been made yet. 
Equity of access and reducing health disparities are key areas of focus of the new NHS Genomic Medicine 
Service, so provision of culturally competent genomic care (CCGC) should be a priority for clinical 
commissioning to ensure all patients are well informed, educated and empowered to benefit from 
genomic advances.  The importance of delivering genomic health services in a culturally competent 
manner is well recognized (Ahmed, Ahmed, Sharif, Sheridan, & Taylor, 2012; Kirk, Tonkin, & Skirton, 2014).  
However, there is no formal cultural competent training or specific guidance available for healthcare 
professionals (HCPs) facilitating access for these populations to genomic studies.  Mainstreaming of 
genomic testing is already posing significant challenges for HCPs, whose genomic knowledge and clinical 
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skills need to be updated so that they can embrace the change in their clinical practice (Patch & Middleton, 
2018). 
 
Challenges of mainstreaming genomic testing 
Many HCPs have graduated in an era in which genetic testing was very restricted and relatively simple, so 
struggle with the interpretation of new genomic results.  They frequently choose to refer to genetics 
services to avoid having to make the choice of testing modality, or to explain genomic results that they do 
not understand or struggle to communicate to patients and families (Christensen et al., 2016).  With the 
advent of mainstreaming, many health disciplines are recognizing the critical importance of genomic 
education for the entire continuum of nursing, midwifery and medical professions (Calzone et al., 2018; 
Kirk et al., 2014; Slade, Subramanian, & Burton, 2016; Tonkin, Skirton, & Kirk, 2018).  However, a cross-
professionals genomics training needs analysis showed that 84.9% of 2578 NHS HCPs felt in need of further 
training and 23% of them felt that they lacked the genomics knowledge required for their current role 
(HEE, 2017).  This highlights the needs for continuing professional development to fill the skills and 
knowledge gaps in the workforce. 
 
Integrating genomic education and training for a wide range of the healthcare workforce poses a 
significant challenge for genomic policy makers, health organizations and professional regulatory and 
training bodies (Slade et al., 2016).  Health Education England was assigned to provide and commission 
genomic education and ensure that HCPs have the knowledge and skills to deliver genomic research and 
healthcare.  A transformation strategy has been developed through the Genomics Education Programme in 
order to increase capacity and capability and to address genomic learning needs of NHS healthcare 
workforce (Simpson, Seller, & Bishop, 2019).  A wide range of formal genomics training courses are now 
available in the UK for all clinical professional groups.  Despite these training programs, educational 
Accepted manuscript 




curricula are inconsistent in their approaches and need to be continually evolved to keep pace with the 
genomic advances. 
 
Existing Frameworks of Cultural Competent training 
Most widely used models of cultural competence in healthcare practice and research have not focused on 
genomics (Campinha-Bacote, 2002; Papadopoulos & Lees, 2002).  A recent UK competence framework for 
consenting for clinical genomic testing refers to language, culture and effective communication (Genomics 
Education Programme, 2019) but there is no further guidance.  Healthcare organizations and professional 
regulatory bodies in the UK including the NHS, General Medical Council, Nursing and Midwifery Council 
and Genetic Counselors Registration Board, have produced policies and educational standards promoting 
culturally competent clinical practice.  However, a review exploring cultural competency training (CCT) for 
HCPs in the UK showed inconsistencies and a lack of ‘institutional commitment’ toward this training 
(George, Thornicroft, & Dogra, 2015) that may also reflect the political nature of the CCT strategy to reduce 
health inequalities rather than a clinically driven strategy, which could influence commissioning of CCT 
training to improve health outcomes more effectively.  McGinniss, Tahmassi, & Ramos’s 2018 review of 
CCT training in genomic education showed the limited evidence supporting the utility and efficacy of these 
training opportunities. 
In order to enhance equity of access for diverse populations in genomic studies and to fill the training and 
knowledge gaps in the healthcare workforce, this paper presents the first cultural competence framework 
for genetic and mainstream HCPs, covering the cultural, genomic and research aspects.  It is unique in 
illustrating the requirements for all of these skills and knowledge in synergy to provide CCGC. 
Approach 
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This framework has emerged from the first author’s evidence-based clinical and research practice over the 
last 20 years in Yorkshire Regional Genetics Service based upon the clinical need to identify rare genes 
responsible for AR disorders in the British Pakistani population.  To achieve this through autozygosity 
mapping studies, recruitment and retention of the targeted group of patients, unaffected siblings, parents 
and second degree relatives, with blood samples being obtained from all, was fundamental.  Previous 
research experience had highlighted that recruitment of British Pakistani families was difficult for the 
clinical team, with language and cultural differences being the most obvious barriers.  Access to individuals 
and families was another challenge, as it was necessary to understand the family hierarchy and power 
balance in order to gain access to those responsible for making decisions.  Therefore, a culturally 
competent approach to engage these families was required. 
Families had been identified through local pediatricians and genetic HCPs.  The first author then contacted 
the family to offer genomic research and organized a further clinic appointment or a home visit for those 
who agreed.  Information about the studies and consent was explained in their preferred language 
(English, Urdu or Punjabi) to obtain informed consent, a detailed medical history, pedigree and family 
blood samples. Over 300 British Pakistani families were recruited for these studies.  DNA samples were 
obtained from 362 affected individuals and 634 unaffected individuals, giving a total of 996 research 
samples.  A total of 35 novel AR genes were identified and the findings have resulted in 59 publications 
(see Supplementary data).  These research findings made carrier testing, prenatal and pre-implantation 
genetic diagnosis possible for multiple genes associated with AR disorders thus providing direct clinical 
benefits to patients in the UK and around the world. 
 
Furthermore, a psychosocial study was performed looking at 222 British Pakistani participants (117 parents 
of children with an AR disorders and 103 of their relatives) and the findings enhanced understanding of the 
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attitudes of British Pakistani families toward prenatal diagnosis and termination of pregnancy (Ahmed et 
al., 2012). 
 
Reflecting on the successful recruitment of a large cohort of British Pakistani families for research studies, 
Kolb’s model of reflection (Kolb, 1984) was applied to identify the key factors determining this success.  
The four stages of this model are: 
1. Concrete Experience: A new experience or situation or reinterpretation of an existing experience. 
2. Reflective Observation: An understanding of the experience and identification of the issues. 
3. Abstract Conceptualization: Reflection provides a new idea, or modifies an existing abstract concept 
(learning from the experience). 
4. Active Experimentation: Application of theoretical knowledge to inform new practice. 
The process of recruitment and engagement of the British Pakistani families in clinical genomic research 
provided the concrete experience and context which allowed identification of the key factors and 
challenges during this process.  Initially this was done by reflecting upon the key HCP knowledge and skills 
that facilitated successful engagement (see supplementary table 1) and the factors impacting upon 
recruitment (see supplementary table 2).  Further reflection and abstract conceptualization considering the 
chronology of research projects from design and set up, to recruitment and retention and then 
dissemination of results led to these factors being categorized under three main themes: culture, genomics 
and research.  This reflection and conceptualization allowed the innovation of a simple, visual model 
(Figure 1), as well as a comprehensive set of competencies (Table 1).  The framework provides an 
evidence-based guide for those offering genomic testing and/or managing genomic or mainstream services 
that do so. 
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Core concepts of the framework 
The framework comprises of three core concepts: cultural competence, genomic competence and research 
competence.  A Venn diagram was selected to visually represent the synergy between the core concepts 
(Figure 1).  The area of overlap between three core concepts represents what is required for the safe, 
ethical and effective delivery of CCGC.  Since none of the core concepts can be practiced successfully 
without effective communication, this is the central concept in this framework, in which the three core 
competences are embedded.  The healthcare system is an encompassing and essential component for all 
of these core concepts since it plays multiple roles including developing culturally competent strategies 
that enhance the inclusion of diverse populations in genomics, enabling workforce training and providing 
resources for genomic education and cultural competence training.  The core concepts are subdivided into 
a number of competence statements (highlighted in bold in Table 1). 
The practice indicators provide a means by which these competences are demonstrated in practice.  As 
genomic testing is offered by a wide range of genetics and mainstream HCPs, levels of current and required 
competence will depend upon area of practice, clinical knowledge and skills.  Assessment of practice 
indicators can highlight the gaps in HCPs’ training needs.  The practice of the core principles of this 
framework will help HCPs identify their individual learning needs and develop the knowledge, skills and 
attitudes required to offer genomic testing in a safe and culturally competent manner for improved health 
outcomes. 
Cultural Competence 
Cultural competence is dependent on both the individual HCP, and the ethos, practice, policies and 
management of the individual organization.  Cultural competence does not occur in a vacuum but in a 
setting that appreciates the cultural diversity of the population.  The development of cultural competence 
approaches will depend on cultural desire (Campinha-Bacote, 2002).  In the genomic context, what this 
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means is the willingness of the HCP and organization to appreciate genetic diversity and understand the 
tendency of some populations to specific genetic conditions and their significant emotional, cultural and 
social impact upon the individual and family. 
 
A myriad of challenges exist that lead to lack of diversity in genomic studies. In view of the origins and 
histories of health disparities, a joint clinical and social science can be a powerful approach, working 
alongside communities to reduce and eliminates these disparities.  Therefore, it is important that 
healthcare organizations and HCPs understand the impact of religious and cultural factors and other social 
and economic determinants of health, as these create barriers to accessing genomics health services and 
develop cultural competent strategies to improve access.  Healthcare organizations must recognize that 
the increasing diversity of the nation requires a clear vision, economic and targeted strategic planning, 
leadership, education and research in order to support cultural competence practices and overcome these 
persistent cultural and organizational barriers. 
 
In order to ensure that genomic datasets represent the diverse nature of the population it serves and to 
prevent bias, scientists and their funders must work in collaboration with healthcare providers and 
promote the inclusion of all ancestries in genomic research.  Therefore, a more global cultural competent 
approach, dedicated organizational leadership, robust economic drive, investment from funding bodies 
and political willingness are all critical factors in facilitating access to genomics for all. 
 
Cultural competence requires that both HCPs and health organizations have the cultural awareness, 
knowledge and skills to deliver genomic care in the cultural context of their diverse populations.  They 
must understand the clinical and scientific imperatives of including diverse populations in genomic studies 
and play a key role in enhancing this inclusion, develop culturally competent strategies to eliminate 
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disparities and facilitate access to genomic healthcare.  Therefore, genomic health policy makers and 
training bodies have a responsibility to ensure that cultural competence training for HCPs is a priority. 
 
On an individual level, it is imperative that HCPs accept cultural differences (Kirk et al., 2014), understand 
how their personal beliefs are socially constructed and are willing to reflect upon these and their own 
stereotypical cultural assumptions (Campinha-Bacote, 2002; McGinniss, Tahmassi, & Ramos, 2018).  This 
requires an intellectual curiosity regarding one’s own culture and that of others, which can enhance one’s 
knowledge of world views, health beliefs, social and religious customs, family dynamics, biological 
variation, as well as improving the healthcare provided.  Further details of key cultural competences 
required by an individual HCP offering genomic studies are provided in Table 1. 
 
Genomic competence 
Genomic competence is the HCP’s knowledge and understanding of genomics and ability to translate this 
clinical knowledge to inform precision medicine.  Mainstream health disciplines will also become involved 
in pharmacogenomics, which involves analyzing genomic variants that influence drug metabolism, so an 
understanding of genomic diversity and the scientific and clinical imperatives of including diverse 
populations in genomic studies is essential.  HCPs offering genomic testing, whether clinical or research, 
have key roles, including consenting, obtaining a detailed phenotype (observable characteristics) for 
patients and their families, sample collection, clinical interpretation of genomic variants and, most 
importantly, communicating this information to patients and families effectively.  The process of gaining 
fully informed consent is already time-consuming and challenging for families but even more difficult for 
families with additional language and cultural barriers.  Informed consent for genomic testing includes the 
possibility that variants of uncertain significance (VUS) and clinically significant secondary findings may be 
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reported back.  Once genomic testing has been instituted, the family may need continual support and 
reassurance as results may take months or years to obtain. 
Many results will be complex and require bioinformatics skills to interpret the potential significance of 
VUS.  In some cases, where potentially pathogenic variants have been identified, the HCP may request 
extra samples, for example skin biopsies from an affected individual or blood samples from the extended 
family to prove, or disprove, pathogenicity.  When diagnostic results or unexpected secondary findings are 
issued, the HCP needs genomic competence in order to understand and explain the diagnosis, prognosis, 
any specific management, inheritance pattern, recurrence risks, reproductive options and implications for 
family members in accordance with their language ability and family dynamics. 
Research competence 
Those planning to recruit patients must understand the research aims, protocol and eligibility criteria so 
they can identify suitable patients.  All UK HCPs involved in research should have undergone Good Clinical 
Practice training, which provides ethical, scientific and practical guidance and standards for conducting 
genomic research.  Genetics HCPs are likely to be involved in research recruitment but may not have wider 
research experience and the same will apply to many senior HCPs and trainees in mainstream specialties.  
HCPs require a good understanding of research and genomics to enable them to explain how testing will be 
performed, what is expected of the families and the timescale of the results. When creating a genomic 
research protocol, it is essential to recognize potential ethical dilemmas such as significant secondary 
findings, carrier data for other disorders, non-paternity or undisclosed/ unknown consanguinity.  These 
ethical issues should also be detailed in patient information leaflets and discussed at recruitment, so it is 
clear what information will be revealed to HCPs and families. 
For rare diseases, blood DNA samples will be required from patients and often their parents, and from 
cancer patients, their tumor sample alongside their blood DNA samples.  HCPs must be aware of 
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professional codes of practice and ethical guidelines and ensure appropriate consent for storage of DNA 
and human tissue samples.  They should be familiar with the consent process and information required for 
potential participants to make informed decisions.  It is the HCP’s responsibility to reassure families about 
the utility, anonymity and security of their stored data.  HCPs may have to contact a family to encourage 
compliance in providing further blood samples, to re-establish contact if there is an extended period of 
time before results become available or to seek consent for publication, which may include photographs of 
a dysmorphic individual. 
Communication 
Effective communication plays a significant role in achieving a therapeutic relationship, bridging cultural 
gaps and effectively addressing health disparities.  Each of the three concepts in this framework is reliant 
on communication and it is the synergy of these central concepts with communication that facilitates 
CCGC.  Communication skills are an essential component: they cannot be viewed as a discrete entity but as 
all-encompassing.  Communication is complex and goes beyond merely the use of language, indeed it is a 
whole package in relation to interpersonal communication.  Effective communication skills are much more 
than just conveying the complex genomic information through written or spoken words but it is about 
considering languages and linguistic, cultural, psychosocial and religious aspects of the communication.  
Communication is a transferable skill which guides HCPs to effectively engage with families and understand 
the communication strategies required to deliver complex genomic information in cultural context of the 
patients and families (Ahmed, 2013; Tonkin et al., 2018). 
Healthcare system 
The implementation of this framework cannot be achieved without the support of the local healthcare 
system.  It is, therefore, seen as an overarching concept of this framework.  Researchers have indicated 
that HCPs’ training needs are inadequately met and the need for genomic education remains challenging 
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(Crellin et al., 2019; Simpson et al., 2019; Slade et al., 2016).  This necessitates further guidance and 
genomic training for HCPs so that they can embrace the unprecedented scope of genomics in their clinical 
and research roles and develop a wide range of competence across multiple areas.  Organizations should 
ensure their workforces have the competence to deliver genomic care in the cultural context of the diverse 
populations.  Organizational policies, strategic vision and leadership, educational standards and curricula 
will play a fundamental role in the implementation and practice of this framework.  Healthcare 
organizations must provide resources (time and funding) for HCPs to develop genomic, cultural and 
research competence.  Training should also be designed using culturally responsive and discipline-specific 
learning outcomes and practice indicators. 
Conclusions 
This competence framework sets out the requirement for HCPs to have genomic competence, cultural 
competence and research competence to provide equitable access to genomic testing, whether on a 
clinical or research basis, in a genomics service or a mainstream specialty.  The knowledge and skills at 
each competence could be developed separately but all three must be applied synergistically.  As this 
whole process is dependent on the practice of effective communication skills and governance of healthcare 
system, deficits in any of these concepts would influence the safety of CCGC and would exacerbate health 
disparities.  The framework needs to be fully tested in practice to ensure it is applicable to all minority 
ethnic groups.  It is anticipated that this framework will improve equity of access to clinical genomic testing 
and lead to increased diversity in genomic studies by encouraging researchers and funders, as well as 
recruiting HCPs to consider cultural competence in their genomic research.  It should guide genetics HCPs, 








The framework was developed by SMS for her PhD with the guidance of supervisory team from University 
of South Wales (MK, ET, RS, JY) and Yorkshire Regional Genetic Service (MB, MA, ES).  All authors have 
been involved in drafting the work or revising it critically for important intellectual content and have 
approved the submitted version. 
Acknowledgements 
The authors would like to thank the British Pakistani families whose participation in genomic research 
helped to identity the key concepts of this practice framework.  SMS would also like to thank Yorkshire 
Regional Genetic Service for providing study time and funding, and Dr Muhammad Sharif, Asad Sharif and 
Sophia Javeed Malik for their practical and technical support during the writing of her thesis and 
development of this framework. 
Conflict of interest statement 
SMS, MK, ET, RS, JY, MB, MA and ES declare that they have no conflict of interest. 
References 
Adeyemo, A., & Rotimi, C. (2014). What does genomic medicine mean for diverse populations? Mol Genet 
Genomic Med, 2, 3-6. doi:10.1002/mgg3.63 
Ahmed, M. (2013). Communication with Pakistani Muslim clients. In J. Wiggins & A. Middleton (Eds.), 
Getting the message across: Overcoming communication challenges in clinical genetics (pp. 90- 
111). Oxford: Oxford University Press. 
Ahmed, S., Ahmed, M., Sharif, S., Sheridan, E., & Taylor, G. (2012). Attitudes towards prenatal testing and 
termination of pregnancy in British Pakistani parents and relatives of children with recessive 
conditions in the UK. Prenat Diagn, 32, 954-959. doi:10.1002/pd.3940 
Bentley, A. R., Callier, S., & Rotimi, C. N. (2017). Diversity and inclusion in genomic research: why the 
uneven progress? J Community Genet, 8, 255-266. doi:10.1007/s12687-017-0316-6 
Accepted manuscript 




Calzone, K. A., Kirk, M., Tonkin, E., Badzek, L., Benjamin, C., & Middleton, A. (2018). The Global Landscape 
of Nursing and Genomics. J Nurs Scholarsh, 50, 249-256. doi:10.1111/jnu.12380 
Campinha-Bacote, J. (2002). The Process of Cultural Competence in the Delivery of Healthcare Services: a 
model of care. J Transcult Nurs, 13, 181-184. doi:10.1177/10459602013003003 
Christensen, K. D., Vassy, J. L., Jamal, L., Lehmann, L. S., Slashinski, M. J., Perry, D. L., . . . MedSeq Project, T. 
(2016). Are physicians prepared for whole genome sequencing? a qualitative analysis. Clin Genet, 
89, 228-234. doi:10.1111/cge.12626 
Cornel, M. C., & Bonham, V. L. (2017). Genomics for all in the 21st century? J Community Genet, 8, 249-
251. doi:10.1007/s12687-017-0333-5 
Crellin, E., McClaren, B., Nisselle, A., Best, S., Gaff, C., & Metcalfe, S. (2019). Preparing Medical Specialists 
to Practice Genomic Medicine: Education an Essential Part of a Broader Strategy. Frontiers in 
Genetics, 10. doi:10.3389/fgene.2019.00789 
Curtis, D. (2018). Polygenic risk score for schizophrenia is more strongly associated with ancestry than with 
schizophrenia. Psychiatr Genet, 28, 85-89. doi:10.1097/YPG.0000000000000206 
Darr, A., Small, N., Ahmad, W. I., Atkin, K., Corry, P., & Modell, B. (2015). Addressing key issues in the 
consanguinity-related risk of autosomal recessive disorders in consanguineous communities: 
lessons from a qualitative study of British Pakistanis. J Community Genet, 7, 65-79. 
doi:10.1007/s12687-015-0252-2 
DDD. (2018). Project Updates.   Retrieved from https://www.ddduk.org/updates.html 
GEL. (2017). The 100,000 Genomes Project Protocol v4.   Retrieved from 
https://www.genomicsengland.co.uk/100000-genomes-project-protocol/ 
GEL. (2018). Secretary of State for Health and Social Care announces ambition to sequence 5 million 
genomes within five years.   Retrieved from https://www.genomicsengland.co.uk/matt-hancock-
announces-5-million-genomes-within-five-years/ 
Accepted manuscript 




GEL. (2019). A public dialogue on genomic medicine: time for a new social contract?  Final report.   
Retrieved from https://www.genomicsengland.co.uk/public-dialogue-report-published/ 
Genetic Alliance UK. (2018). What is a rare disease?   Retrieved from 
https://www.raredisease.org.uk/what-is-a-rare-disease/ 
Genomics Education Programme. (2019). Facilitating genomic testing: A competency framework; A cross-
professional competency framework to facilitate and consent patients for genomic testing.   
Retrieved from https://www.genomicseducation.hee.nhs.uk/consent-a-competency-framework/ 
George, R., Thornicroft, G., & Dogra, N. (2015). Exploration of cultural competency training in UK 
healthcare settings: A critical interpretive review of the literature. Diversity & Equality in Health & 
Care, 12, 104-115. doi:10.21767/2049-5471.100037 
Hamamy, H., Antonarakis, S. E., Cavalli-Sforza, L. L., Temtamy, S., Romeo, G., Kate, L. P., . . . Bittles, A. H. 
(2011). Consanguineous marriages, pearls and perils: Geneva International Consanguinity 
Workshop Report. Genet Med, 13, 841-847. doi:10.1097/GIM.0b013e318217477f 
HEE. (2017). Embedding Genomics in Nursing and Midwifery Retrieved from 
https://www.genomicseducation.hee.nhs.uk/wp-content/uploads/2019/06/Genomics-nursing-
midwifery-Report-June-2017.pdf 
Kirk, M., Tonkin, E., & Skirton, H. (2014). An iterative consensus-building approach to revising a 
genetics/genomics competency framework for nurse education in the UK. J Adv Nurs, 70, 405-420. 
doi:10.1111/jan.12207 
Kolb, D. (1984). Experiential Learning: experience as the source of learning and development (1 ed.). 
NJ:Prentice Hall: Englewood Cliffs, Prentice-Hall. 
Martin, A. R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B. M., & Daly, M. J. (2019). Clinical use of current 
polygenic risk scores may exacerbate health disparities. Nat Genet, 51, 584-591. 
doi:10.1038/s41588-019-0379-x 
Accepted manuscript 




Martin, H. C., Jones, W. D., McIntyre, R., Sanchez-Andrade, G., Sanderson, M., Stephenson, J. D., . . . Study, 
D. D. D. (2018). Quantifying the contribution of recessive coding variation to developmental 
disorders. Science, 362, 1161-1164. doi:10.1126/science.aar6731 
Mathew, S. S., Barwell, J., Khan, N., Lynch, E., Parker, M., & Qureshi, N. (2017). Inclusion of diverse 
populations in genomic research and health services: Genomix workshop report. J Community 
Genet, 8, 267-273. doi:10.1007/s12687-017-0317-5 
McGinniss, M. A., Tahmassi, A. G., & Ramos, E. (2018). Towards Cultural Competence in the Genomic Age: 
a Review of Current Health Care Provider Educational Trainings and Interventions. Current Genetic 
Medicine Reports, 6, 187- 198. doi:10.1007/s40142-018-0150-0 
Mills, M. C., & Rahal, C. (2019). A scientometric review of genome-wide association studies. 
Communications Biology, 2, 9. doi:10.1038/s42003-018-0261-x 
Narasimhan, V. M., Hunt, K. A., Mason, D., Baker, C. L., Karczewski, K. J., Barnes, M. R., . . . van Heel, D. A. 
(2016). Health and population effects of rare gene knockouts in adult humans with related parents. 
Science, 352, 474-477. doi:10.1126/science.aac8624 
NHSE. (2018). NHS Genomic Medicine Service Retrieved from https://www.england.nhs.uk/genomics/nhs-
genomic-med-service/ 
ONS. (2011). Regional ethnic diversity.   Retrieved from https://www.ethnicity-facts-
figures.service.gov.uk/uk-population-by-ethnicity/national-and-regional-populations/regional-
ethnic-diversity/latest 
Papadopoulos, I., & Lees, S. (2002). Developing culturally competent researchers. J Adv Nurs, 37, 258-264. 
doi:abs/10.1046/j.1365-2648.2002.02092.x 
Patch, C., & Middleton, A. (2018). Genetic counselling in the era of genomic medicine. Br Med Bull, 126, 27-
36. doi:10.1093/bmb/ldy008 
Accepted manuscript 




Saleheen, D., Natarajan, P., Armean, I. M., Zhao, W., Rasheed, A., Khetarpal, S. A., . . . Kathiresan, S. (2017). 
Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature, 
544, 235-239. doi:10.1038/nature22034 
Salway, S., Yazici, E., Khan, N., Ali, P., Elmslie, F., Thompson, J., & Qureshi, N. (2019). How should health 
policy and practice respond to the increased genetic risk associated with close relative marriage? 
results of a UK Delphi consensus building exercise. BMJ Open, 9, e028928. doi:10.1136/bmjopen-
2019-028928 
Sanderson, S. C., Diefenbach, M. A., Zinberg, R., Horowitz, C. R., Smirnoff, M., Zweig, M., . . . Richardson, L. 
D. (2013). Willingness to participate in genomics research and desire for personal results among 
underrepresented minority patients: a structured interview study. J Community Genet, 4, 469-482. 
doi:10.1007/s12687-013-0154-0 
Sheridan, E., Wright, J., Small, N., Corry, P. C., Oddie, S., Whibley, C., . . . Parslow, R. C. (2013). Risk factors 
for congenital anomaly in a multiethnic birth cohort: an analysis of the Born in Bradford study. 
Lancet, 382, 1350-1359. doi:10.1016/S0140-6736(13)61132-0 
Simpson, S., Seller, A., & Bishop, M. (2019). Using the Findings of a National Survey to Inform the Work of 
England's Genomics Education Programme. Front Genet, 10, 1265. doi:10.3389/fgene.2019.01265 
Sirugo, G., Williams, S. M., & Tishkoff, S. A. (2019). The Missing Diversity in Human Genetic Studies. Cell, 
177, 1080. doi:10.1016/j.cell.2019.04.032 
Skyers, S. (2018). 100,000 Genomes Project, Black African and Black Caribbean Communities. A Qualitative 
Exploration of Views on Participation.   Retrieved from https://www.genomicsengland.co.uk/wp-
content/uploads/2018/07/black-african-black-caribbean-communities-participation-100kgp.pdf 
Slade, I., Subramanian, D. N., & Burton, H. (2016). Genomics education for medical professionals - the 
current UK landscape. Clin Med (Lond), 16, 347-352. doi:10.7861/clinmedicine.16-4-347 
Accepted manuscript 




Tonkin, E. T., Skirton, H., & Kirk, M. (2018). The first competency based framework in genetics/genomics 
specifically for midwifery education and practice. Nurse Educ Pract, 33, 133- 140. 
doi:10.1016/j.nepr.2018.08.015 
Woods, C. G., Cox, J., Springell, K., Hampshire, D. J., Mohamed, M. D., McKibbin, M., . . . Inglehearn, C. F. 
(2006). Quantification of homozygosity in consanguineous individuals with autosomal recessive 









Figure 1: Visual representation of competence framework 
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Table1: Key competences (bold) and practice indicators of competence framework for clinical genomic care and research 
Cultural Competence Genomic competence Research competence 
Study preparation phase: Research protocol, funding, approvals; Research infrastructure; Patient information 
Promote equity of access for under-represented diverse 
populations in clinical genomic research 
 Understand factors contributing to disparities 
 Ensure inclusion criteria appreciate diversity of population 
and  protocol will achieve stated aims 
 Engage diverse populations in research protocol 
development and throughout the research process 
 Consider ethical, legal and cultural issues with regard to 
consent, data storage and publication, especially in view of 
consanguinity and potentially relevant information for the 
wider family 
Develop strategies to improve access to clinical genomic 
research  
 Identify cultural practices, preferences and language needs 
of local population 
 Seek guidance and input from culturally competent HCPs to 
develop strategies to improve access 
 Seek funding for research staff who speak required 
language(s) +/- interpreting services 
 Understand cultural and religious perspectives  
 Ensure patient information leaflets and consent forms are 
in accordance with likely language ability and translated 
appropriately 
 Ensure funding for cultural competency training for 
recruiting HCPs if required 
Demonstrate knowledge and understanding of the 
underpinning scientific principles of genomic testing that 
inform clinical practice and impact patient clinical pathways 
 Recognize training needs e.g. advances in genomics, change 
in practice and ensure access to appropriate programs 
 Understand disease mechanism, biological variation,  clinical 
manifestation, variability of genetic disorders and 
interpretation of new genomic results 
 Understand the increased frequency of certain genetic 
disorders in specific ethnic population and scientific 
imperative for ethnic diversity in genomic research 
 Consider various modalities of genomic testing and 
availability of clinical and research testing 
 Appreciate the clinical/pharmacogenomics benefits of clinical 
genomic research  
 Identify potential participants who would be eligible and 
benefit from clinical genomic research 
 Understand scientific and ethical issues underpinning clinical 
practice 
 Understand principles of mental capacity laws 
 Recognize potential for secondary findings and ensure 
policies are in place to feed these back if appropriate 
 Design patient information leaflets and consent forms 
covering relevant genomic concepts, limitations of genomic 
testing and possibility of secondary findings 
Contribute to protocol development in line with 
organizational policies and governance framework of 
clinical genomic research 
 Identify and apply to relevant funding agencies 
 Obtain research and ethical approvals 
 Consider ethical and legal issues with regard to consent 
and DNA/tissue sample storage  
 Review any potential barriers to participation (e.g. 
requirements to provide clinical photographs if this 
could be an option) 
 Ensure patient information leaflets and consent forms 
are in language that will be understood by lay people 
Identify training and educational needs of the HCPs 
undertaking the recruitment process - capacity building 
and infrastructure 
 Identify who will recruit: HCPs as part of routine clinical 
and/ or dedicated research staff? 
 Ensure access to research skills training 
 Make all relevant HCPs aware of research aims, 
protocol, inclusion & exclusion criteria, expectations of 
participants and process of recruitment 
Recruitment phase: Participants recruitment, informed consent; Phenotyping and DNA sample collection, Phenotyping entry and Data Storage 
Promote effective communication and ensure adequate 
translation  
 Consider literacy levels of local diverse population  
 Promote communication skills (e.g.  paraphrasing and 
Identify potential participants who would be eligible and 
benefit from clinical genomic research 
 Be able to explain research aims, protocol, inclusion & 
exclusion criteria, expectations of participants and routes of 
Understand research process 
 Understand professional codes of practice and 
legislation 
 Know aims, protocol, inclusion & exclusion criteria, 
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 Provision of interpreters 
 Provision of appropriate patient information leaflets 
 Maintain confidentiality 
Demonstrate cultural desire, sensitivity and cultural 
knowledge in understanding the impact of psychosocial 
issues on decision-making 
 Examine and challenge personal values and beliefs 
 Understand societal influence on personal values and 
beliefs and other social determinant of health 
 Recognize impact of family hierarchy, religion, health 
beliefs and values on decision-making 
 Avoid stereotypical assumptions or cultural imposition 
 Show cultural sensitivity and show respect for cultural 
differences e.g. consanguinity 
 Understand family dynamics and potential for head of 
household (etc) to make decisions for, or influence, others, 
while ensuring that valid consent is provided 
 Promote and facilitate individual’s autonomy in  
 decision-making 
 Understand motivations/perspective of patients/families 
and impact of timing e.g. during active treatment, 
bereavement 
recruitment when seeing patients in clinic 
 Explain potential benefit of research to individual patients/ 
families and to genomic knowledge 
Explain relevant genomic information in an appropriate and 
sensitive manner 
 Collect accurate phenotyping data and draw detailed 
pedigrees  
 Utilize diagrams for genomic concepts e.g. genes, 
chromosomes and pattern of inheritance 
 Describe benefits, limitations and uncertainty  of genomic 
testing and enhance patients genomic literacy  
 Understand patients’ perspective and concerns 
 Delineate potential timescales for results 
Remember dual role and put patient care before research 
 Emphasize the implications of diagnostic results for the 
patient, immediate family and wider family 
 Develop therapeutic alliance and offer on-going emotional 
support 
 Balance families’ hopes and expectations from genetic 
testing, as result may be inconclusive  
 Explain the possibility of secondary findings and potential 
implications of diagnostic results or secondary findings for 
patients, children and family  
 Explain potential impact of genomic results on insurance 
expectations of participants and routes of recruitment 
 Identify and approach potential participants 
 
Explain all information required for a fully informed 
consent process 
 Understand key principals of informed consent, 
including the right to withdraw 
 Provide patient information leaflets and be prepared to 
answer queries and to give potential participants time 
to fully consider and discuss the study with others 
before recruitment 
 Allow adequate time and space for a consent 
appointment, including time for questions 
 Recognize and respond to non-verbal clues that family 
are confused, upset etc 
 Utilize diagrams for difficult research concepts 
 Be non-directive, non-judgmental and respect decisions 
to decline participation 
 Gain informed consent in accordance with good 
research practice guidelines and reassure families about 
confidentiality of stored data 
 Obtain DNA samples from participants, with on-going 
consent and further DNA samples if required. 
 Arrange transportation of samples and notification of 
laboratory 
Retention phase: Genomic analysis and result interpretation and validation 
Establish therapeutic relationship and continuity of care 
 Maintain effective communication with the family 
depending upon their level of literacy, knowledge and age  
 Respond if families have questions during study 
 Establish rapport with family 
 Establish patients understanding and expectation of 
genomic testing 
 Maintain ability to return to wider family to seek further 
samples if helpful to confirm/ refute findings 
 Be mindful of social circumstances influencing consent 
Understand the importance of genomic result for families  
 Identify needs of participants and families while awaiting 
results 
 Recognize circumstances when results should be chased up 
e.g. to offer prenatal diagnosis for at risk pregnancy 
 Recognize when further diagnostic testing should be 
organized, even if this is detrimental to research 
 Contribute to MDT discussion for interpretation of primary & 
secondary findings 
 Arrange confirmation in accredited diagnostic laboratory 
Maintain on-going support and contact with family  
 Provide contact details (ideally more than one route) 
 Reassure about timescales for results 
 Encourage patients to comply with study e.g. if further 
samples needed 
 Offer support if have any concerns  
 Manage patients expectations, remaining aware of 
limitations of genomic testing and not giving false hope 
 Remain aware of ethical dilemmas of dual roles as 
researcher and HCP 
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process and hindering retention  
 Consider welfare and support needs of participants that 
may impede retention 
 Maintain professional boundaries 
 Remain mindful and put in place (where applicable) 
information and disclosure pathways for extended family 
 Ensure families are aware of timescale for accredited results 
 Recognize limitation of one’s own genomic knowledge and 
ask for help or refer to colleague with expertise for further 
clinical input 
 
 Maintain confidentiality 
 Respect autonomy and right to withdraw from study 
 Remain aware of individual learning needs and request 
further training  
 Contribute to MDT meetings and maintain contact with 
Genomic Laboratory and referring clinician. 
Results phase: Feedback for clinicians and patients; Personalized management; Publications 
Recognize significance of genomic information in cultural 
context of the family  
 Consider cultural or language barriers to communication 
 Use interpreters as required and maintain family 
confidentiality  
 Offer psychological support and be aware of their mental, 
physical and social well-being 
 Refer to support agencies and liaise with school etc if 
required to tailor services  
 Offer follow-up to help family understand results and 
implications 
 Encourage disclosure of genomic information to at-risk 
family members 
 Understand patient concerns about disclosure of genomic 
information and facilitate the disclosure process 
 Offer support to at-risk family members and explain referral 
pathway if carrier testing requested 
 Sensitive discussion about consanguinity and risks for 
subsequent generations 
 Recognize the impact of genomic result on personal values, 
religious concerns and family dynamics 
 Offer support if genetic testing did not provide a clear 
answer and discuss options for possible future testing 
 Provide information on patient resources/ support groups  
 Maintain continuity of care and provide point of contact 
Understand utility and implication of genomic results  
for individual patient and family to guide clinical management 
 Explain diagnostic results, clinical implications and secondary 
findings to families  
 Disseminate results to patient’s referring physician, primary 
care and other HCPs 
 Consider any specific management plan or targeted 
therapeutic interventions and clinical pathways 
 Offer details of genetic counseling and describe genetic 
concepts e.g. mode of inheritance 
 Delineate family risks and discuss reproductive options e.g. 
prenatal or pre-implantation genetic diagnosis 
 Provide support to deal with the personal, emotional and 
psychosocial aspects of genomic information 
 Provide access to family for carrier or predictive testing 
 Be aware of principles of childhood testing. 
 Encourage disclosure of genomic information to at-risk family 
members 
 Demonstrate evidence based practice and contribute to 
publications/presentations  
 Obtain up-to-date phenotype if required 
 Request consent and organize additional clinical photographs 
if required 
 Encourage laboratories to offer testing for newly discovered 
genes, so that testing will be available for other families 
Provide summary of research findings and disseminate 
genomic knowledge 
 Ensure results are provided to HCP responsible for 
patient’s care 
 Prepare publications to disseminate research findings 
 Seek consent from families for the inclusion of 
identifiable information e.g. clinical photographs or 
detailed pedigrees in publications 
 Understand data protection principles and assure 
families of anonymity 
 Understand social factors and family dynamics that may 
influence participant’s choice to consent for publication 
 Respect autonomy and right to decline 
 Provide copies of relevant articles to families 
 Provide a written summary of research findings to 
participants 
 
Some items fit exclusively on one list, some mainly on one list and equally between two lists.  The latter group is shown in italics for clarity. 
MDT: multi-disciplinary team  
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Supplementary table 1: Key factors that facilitated successful engagement of the British Pakistani population in clinical genomic research 
Communication skills Cultural understanding Genomic knowledge Research skills 
 Development of therapeutic alliance 
 Limited English language skills and 
education - need appropriate 
strategies to explain complex 
genomic concepts in simple manner 
 Detailed consent forms and 
participant information leaflets 
 Ability to communicate at inter-
generational level 
 Offer family-centered approach 
 Effective use of interpreters - need to 
confirm with the family 
 Explain results to families and inform 
referring physicians 
 Encourage and promote disclosure of 
genetic results to at risk relatives 
 Provision of psychological support  
 
 Social and cultural aspects of 
consanguinity 
 Impact of rare genetic disorders on 
entire family 
 Appreciates religious beliefs, cultural 
values & their influence on decision 
making 
 Perceived healthcare models 
 Complex family dynamics - influence 
on decision making 
 Cultural sensitivity to overcoming 
family dynamics and, in turn, 
facilitating women’s autonomy 
 Understand practical and financial 
difficulties and other social 
determinants of health 
 Clinical /diagnostic importance of 
inclusion of British Pakistani families 
in genomic research 
 Provision of genetic counseling 
 Appropriate strategies to explain 
complex genomic concepts in simple 
manner 
 Discuss potential benefits and 
limitation of genomic testing 
 Confidentiality and ethical 
considerations, including family 
disclosure 
 Understand timescale of results 
 Recognize testing may not provide 
answers 
 Implications of possible secondary 
findings 
 Balancing hope and expectations 
 Explain results to families and inform 
referring physicians 
 Encourage and promote disclosure of 
genetic results to at risk relatives 
 Coordinating clinical referrals  
 Recognizing need for pursuing urgent 
results for e.g.  for prenatal testing 
 Training needs of mainstream HCPs  
 Wider community engagement and 
education 
 Detailed consent forms and 
participant information leaflets 
 Ability to explain the aims and 
process of research study  
 Family ascertainment and data 
collection 
 Facilitate informed decision making 
process 
 Confidentiality and ethical 
considerations, including family 
disclosure 
 Safeguarding and utility of data 
 Understand timescale of results 
 Maintain on-going follow up and 









Supplementary table 2: Factors impacting upon recruitment of the British Pakistani population for clinical genomic research 
Factors affecting the patient/ family Factors affecting the HCP Factors affecting the patient/ family and the HCP 
 Higher incidence of consanguineous marriages 
 Increase risk of AR disorders 
 Relatives are at risk of having an affected child 
Burden of undiagnosed rare AR disorders 
 Fear, uncertainty and lack of clinical pathways 
 Emotional, psychosocial and financial 
Communication barriers 
 To access genomic services and utility of information 
 Challenge of understanding genomic concepts that 
have no direct translation in native language  
 Expect HCPs to provide direct advice  
 Strong religious beliefs 
 Families are less likely to accept genetic causation or 
consider ToP, so may not see utility of a diagnosis 
 Lack knowledge of the Islamic fatwā ( Islamic 
Verdict) regarding ToP 
 Seeks advice from family or religious leaders  
Family dynamics 
 Influence on decision making for carrier testing, 
reproductive options and research recruitment 
 May compromise women’s autonomy 
Non-disclosure of genomic information  
 Impact on family marriages practice 
 Practical barriers 
 Additional appointments - time consuming, work 
pressure and financial implications 
 Multiple blood samples from affected individuals, 
their parents and wider family 
 Diagnostic odyssey 
 Lack of molecular diagnostic techniques and inability 
to guide patient clinical pathway and manage family 
expectations, e.g. treatment and prenatal testing  
Communication barriers:  
 Inability to speak relevant language and difficulty in 
explaining genomic information in cultural context 
 Need communication strategies that help explain 
genetic condition, inheritance pattern, recurrence 
risk and reproductive options  
 Understanding cultural framing of this group 
 Ethical considerations 
 Families expect HCPs to provide direct advice 
 Reliance on family members to interpret and convey 
Information; risk of withholding clinical information  
 Appropriate use of interpreters- risk of withholding 
clinical information; maintain confidentiality 
 Confidentiality of data storage and sharing  
 Implications of possible additional findings 
Family dynamics and cultural beliefs 
 Cultural sensitivity in overcoming religious and 
cultural beliefs, family dynamics and its influence on 
decision making e.g. ToP  
Non-disclosure of genomic information 
 Challenging for HCPs if caring for other relatives 
 Patient confidentiality versus family right to know  
 Practical barriers 
 Lengthy genetic counseling session - time pressures 
 To manage additional hospital appointments and 
ascertainment of multiple biological samples  
 Families need on-going support 
Diagnostic odyssey 
 Lack of clinical diagnosis - challenge for both  
 Limitation of genetic testing - impact on carrier 
testing and reproductive options  
 Communication barriers 
 Complex  genomic information to give/understand 
 A detailed research process and requirement 
 Perception that HCPs oppose consanguinity  
 Power dynamics - HCPs and families perspectives  
 Implications of possible additional findings e.g. 
cancer risk  
Strong religious beliefs 
 Acceptance of genetic diagnosis and utility of 
genomic information - pressure of meeting the 
deadline of the fatwā in prenatal genetic  
 Pressure to incorporate advice from family members 
and religious leader  
Family dynamics 
 Influence on decision making for carrier testing, 
reproductive options and research recruitment 
 May compromise women’s autonomy 
Non-disclosure of genomic information  
 Confidentiality versus family right to know 
 Practical barriers 
 Lengthy genetic counseling session - time pressures 
for families and HCPs 
 Ascertainment of multiple biological samples  
Timescale of research finding and follow up care 
 Frustration due to uncertain timescale of time 
 To manage family expectations, e.g. treatment, 
prenatal testing and maintaining follow up  
ToP: termination of pregnancy 
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